help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jordan, V. C.
Right arrow Articles by Morrow, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, V. C.
Right arrow Articles by Morrow, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Breast Cancer
Hazardous Substances DB
*TAMOXIFEN
Endocrine Reviews 20 (3): 253-278
Copyright © 1999 by The Endocrine Society

Tamoxifen, Raloxifene, and the Prevention of Breast Cancer1

V. Craig Jordan and Monica Morrow

Departments of Molecular Pharmacology, Biological Chemistry (V.C.J.), and Surgery (M.M.), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611

I. Introduction
II. Lacassagne’s Prevention Principle: A Target and an Estrogen Antagonist
III. Tamoxifen as an Antitumor Agent
A. ER status and the duration of tamoxifen
B. Contralateral breast cancer
C. Endometrial cancer
D. Conclusions
IV. Selective Estrogen Receptor Modulation
A. Antiestrogen activity at the ER
B. Coactivators for ER
C. Alternate response elements on DNA
D. An alternate ER-ERß
V. Biological Basis for Tamoxifen as a Breast Cancer Preventive
A. Animal models
B. Bones
C. Lipids
D. Uterus
VI. Risk Factors for Breast Cancer
A. Interactions among risk factors
B. Identification of candidates for chemoprevention
VII. Prevention of Breast Cancer with Tamoxifen
A. Royal Marsden Pilot Study
B. NSABP/NCI Study
C. Italian study
D. Conclusions
VIII. Biological Basis for Raloxifene as a Breast Cancer Preventive
A. Antitumor actions
B. Bones
C. Lipids
D. Uterus
IX. Study of Tamoxifen And Raloxifene (STAR)
X. The Future of Prevention




This article has been cited by other articles:


Home page
 J Mol EndocrinolHome page
N. Kimura, N. Takamatsu, Y. Yaoita, R Y. Osamura, and N. Kimura
Identification of transcriptional regulatory elements in the human somatostatin receptor sst2 promoter and regions including estrogen response element half-site for estrogen activation
J. Mol. Endocrinol., February 1, 2008; 40(2): 75 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
I. Kryczek, S. Wei, E. Keller, R. Liu, and W. Zou
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis
Am J Physiol Cell Physiol, March 1, 2007; 292(3): C987 - C995.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Albanito, A. Madeo, R. Lappano, A. Vivacqua, V. Rago, A. Carpino, T. I. Oprea, E. R. Prossnitz, A. M. Musti, S. Ando, et al.
G Protein-Coupled Receptor 30 (GPR30) Mediates Gene Expression Changes and Growth Response to 17{beta}-Estradiol and Selective GPR30 Ligand G-1 in Ovarian Cancer Cells
Cancer Res., February 15, 2007; 67(4): 1859 - 1866.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Padron, L. Li, E. M. Kofoed, and F. Schaufele
Ligand-Selective Interdomain Conformations of Estrogen Receptor-{alpha}
Mol. Endocrinol., January 1, 2007; 21(1): 49 - 61.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Berghofer, T. Frommer, G. Haley, L. Fink, G. Bein, and H. Hackstein
TLR7 Ligands Induce Higher IFN-{alpha} Production in Females
J. Immunol., August 15, 2006; 177(4): 2088 - 2096.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y. H. Ju, K. F. Allred, C. D. Allred, and W. G. Helferich
Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations
Carcinogenesis, June 1, 2006; 27(6): 1292 - 1299.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. J. Handelsman
The Rationale for Banning Human Chorionic Gonadotropin and Estrogen Blockers in Sport
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1646 - 1653.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Vivacqua, D. Bonofiglio, A. G. Recchia, A. M. Musti, D. Picard, S. Ando, and M. Maggiolini
The G Protein-Coupled Receptor GPR30 Mediates the Proliferative Effects Induced by 17{beta}-Estradiol and Hydroxytamoxifen in Endometrial Cancer Cells
Mol. Endocrinol., March 1, 2006; 20(3): 631 - 646.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J. H. Kim, M. H. Lee, B. J. Kim, J. H. Kim, S. J. Han, H. Y. Kim, and M. R Stallcup
Role of aspartate 351 in transactivation and active conformation of estrogen receptor {alpha}
J. Mol. Endocrinol., December 1, 2005; 35(3): 449 - 464.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
J. M. Hall and D. P. McDonnell
Coregulators in Nuclear Estrogen Receptor Action: From Concept to Therapeutic Targeting
Mol. Interv., December 1, 2005; 5(6): 343 - 357.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. Huang, X. Li, C. A. Maguire, R. Hilf, R. A. Bambara, and M. Muyan
Binding of Estrogen Receptor {beta} to Estrogen Response Element in Situ Is Independent of Estradiol and Impaired by Its Amino Terminus
Mol. Endocrinol., November 1, 2005; 19(11): 2696 - 2712.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. Chen, H. Pan, L. Zhu, Y. Deng, and J. W. Pollard
Progesterone Inhibits the Estrogen-Induced Phosphoinositide 3-Kinase->AKT->GSK-3{beta}->Cyclin D1->pRB Pathway to Block Uterine Epithelial Cell Proliferation
Mol. Endocrinol., August 1, 2005; 19(8): 1978 - 1990.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
W. Jin, K. Y. Arai, G. Watanabe, A. K. Suzuki, S. Takahashi, and K. Taya
The Stimulatory Role of Estrogen on Sperm Motility in the Male Golden Hamster (Mesocricetus auratus)
J Androl, July 1, 2005; 26(4): 478 - 484.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Tamrazi, K. E. Carlson, A. L. Rodriguez, and J. A. Katzenellenbogen
Coactivator Proteins as Determinants of Estrogen Receptor Structure and Function: Spectroscopic Evidence for a Novel Coactivator-Stabilized Receptor Conformation
Mol. Endocrinol., June 1, 2005; 19(6): 1516 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly
Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists
Endocr. Rev., May 1, 2005; 26(3): 400 - 422.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Hung
Suppression of ps20 Expression in the Rat Uterus by Tamoxifen and Estrogens
Endocrinology, May 1, 2005; 146(5): 2388 - 2396.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Gauduchon, F. Gouilleux, S. Maillard, V. Marsaud, J.-M. Renoir, and B. Sola
4-Hydroxytamoxifen Inhibits Proliferation of Multiple Myeloma Cells In vitro through Down-Regulation of c-Myc, Up-Regulation of p27Kip1, and Modulation of Bcl-2 Family Members
Clin. Cancer Res., March 15, 2005; 11(6): 2345 - 2354.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
J E Sanchez-Criado, J M. de las Mulas, C Bellido, R Aguilar, and J C Garrido-Gracia
Gonadotrope oestrogen receptor-{alpha} and -{beta} and progesterone receptor immunoreactivity after ovariectomy and exposure to oestradiol benzoate, tamoxifen or raloxifene in the rat: correlation with LH secretion
J. Endocrinol., January 1, 2005; 184(1): 59 - 68.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
H. Zhang, T. McElrath, W. Tong, and J. W Pollard
The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation
J. Endocrinol., January 1, 2005; 184(1): 129 - 140.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L Hilakivi-Clarke, C Wang, M Kalil, R Riggins, and R G Pestell
Nutritional modulation of the cell cycle and breast cancer
Endocr. Relat. Cancer, December 1, 2004; 11(4): 603 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
C. Osipo, H. Liu, K. Meeke, and V. C. Jordan
The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death
Experimental Biology and Medicine, September 1, 2004; 229(8): 722 - 731.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. J. Jeong, H. Lin, and M. Hu
Disposition Mechanisms of Raloxifene in the Human Intestinal Caco-2 Model
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 376 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Tamrazi, K. E. Carlson, and J. A. Katzenellenbogen
Molecular Sensors of Estrogen Receptor Conformations and Dynamics
Mol. Endocrinol., December 1, 2003; 17(12): 2593 - 2602.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Kakizoe
Chemoprevention of Cancer - Focusing on Clinical Trials
Jpn. J. Clin. Oncol., September 1, 2003; 33(9): 421 - 442.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. M. Hall and K. S. Korach
Stromal Cell-Derived Factor 1, a Novel Target of Estrogen Receptor Action, Mediates the Mitogenic Effects of Estradiol in Ovarian and Breast Cancer Cells
Mol. Endocrinol., May 1, 2003; 17(5): 792 - 803.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Hui, G. L. Finney, J. S. Carroll, C. S. L. Lee, E. A. Musgrove, and R. L. Sutherland
Constitutive Overexpression of Cyclin D1 but not Cyclin E Confers Acute Resistance to Antiestrogens in T-47D Breast Cancer Cells
Cancer Res., December 1, 2002; 62(23): 6916 - 6923.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
P. Yi, S. Bhagat, R. Hilf, R. A. Bambara, and M. Muyan
Differences in the Abilities of Estrogen Receptors to Integrate Activation Functions Are Critical for Subtype-Specific Transcriptional Responses
Mol. Endocrinol., August 1, 2002; 16(8): 1810 - 1827.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
D. E. DLUZEN and J. L. McDERMOTT
Estrogen, Anti-Estrogen, and Gender: Differences in Methamphetamine Neurotoxicity
Ann. N.Y. Acad. Sci., June 1, 2002; 965(1): 136 - 156.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
P. Yi, M. D. Driscoll, J. Huang, S. Bhagat, R. Hilf, R. A. Bambara, and M. Muyan
The Effects of Estrogen-Responsive Element- and Ligand-Induced Structural Changes on the Recruitment of Cofactors and Transcriptional Responses by ER{alpha} and ER{beta}
Mol. Endocrinol., April 1, 2002; 16(4): 674 - 693.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
R. V. Weatherman, C.-Y. Chang, N. J. Clegg, D. C. Carroll, R. N. Day, J. D. Baxter, D. P. McDonnell, T. S. Scanlan, and F. Schaufele
Ligand-Selective Interactions of ER Detected in Living Cells by Fluorescence Resonance Energy Transfer
Mol. Endocrinol., March 1, 2002; 16(3): 487 - 496.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. M. Klinge, S. C. Jernigan, and K. E. Risinger
The Agonist Activity of Tamoxifen Is Inhibited by the Short Heterodimer Partner Orphan Nuclear Receptor in Human Endometrial Cancer Cells
Endocrinology, March 1, 2002; 143(3): 853 - 867.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. D. Baxter, P. Goede, J. W. Apriletti, B. L. West, W. Feng, K. Mellstrom, R. J. Fletterick, R. L. Wagner, P. J. Kushner, R. C. J. Ribeiro, et al.
Structure-Based Design and Synthesis of a Thyroid Hormone Receptor (TR) Antagonist
Endocrinology, February 1, 2002; 143(2): 517 - 524.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
E. BARRETT-CONNOR
Raloxifene: Risks and Benefits
Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 295 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Suh, A. L. Glasebrook, A. D. Palkowitz, H. U. Bryant, L. L. Burris, J. J. Starling, H. L. Pearce, C. Williams, C. Peer, Y. Wang, et al.
Arzoxifene, a New Selective Estrogen Receptor Modulator for Chemoprevention of Experimental Breast Cancer
Cancer Res., December 1, 2001; 61(23): 8412 - 8415.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
K. D. R. Setchell
Soy Isoflavones--Benefits and Risks from Nature's Selective Estrogen Receptor Modulators (SERMs)
J. Am. Coll. Nutr., October 1, 2001; 20(90005): 354S - 362.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
D. Lu, Y. Kiriyama, K. Y. Lee, and V. Giguere
Transcriptional Regulation of the Estrogen-inducible pS2 Breast Cancer Marker Gene by the ERR Family of Orphan Nuclear Receptors
Cancer Res., September 1, 2001; 61(18): 6755 - 6761.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. C. Jordan
Selective Estrogen Receptor Modulation: A Personal Perspective
Cancer Res., August 1, 2001; 61(15): 5683 - 5687.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
D. Marcantonio, L. E. Chalifour, M. A. Alaoui-Jamali, L. Alpert, and H. T. Huynh
Cloning and Characterization of a Novel Gene That Is Regulated by Estrogen and Is Associated with Mammary Gland Carcinogenesis
Endocrinology, June 1, 2001; 142(6): 2409 - 2418.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
M. Levine, J.-M. Moutquin, R. Walton, and J. Feightner
Chemoprevention of breast cancer: A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer
Can. Med. Assoc. J., June 1, 2001; 164(12): 1681 - 1690.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
H. Liu, E.-S. Lee, A. D. L. Reyes, J. W. Zapf, and V. C. Jordan
Silencing and Reactivation of the Selective Estrogen Receptor Modulator-Estrogen Receptor {{alpha}} Complex
Cancer Res., May 1, 2001; 61(9): 3632 - 3639.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
D. Lu and V. Giguere
Requirement of Ras-Dependent Pathways for Activation of the Transforming Growth Factor {beta}3 Promoter by Estradiol
Endocrinology, February 1, 2001; 142(2): 751 - 759.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. J. Bentrem, R. C. Dardes, H. Liu, J. MacGregor-Schafer, J. W. Zapf, and V. C. Jordan
Molecular Mechanism of Action at Estrogen Receptor {{alpha}} of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen
Endocrinology, February 1, 2001; 142(2): 838 - 846.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
F. Sauvé, L. D. B. McBroom, J. Gallant, A. N. Moraitis, F. Labrie, and V. Giguère
CIA, a Novel Estrogen Receptor Coactivator with a Bifunctional Nuclear Receptor Interacting Determinant
Mol. Cell. Biol., January 1, 2001; 21(1): 343 - 353.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
F. Schaufele, C.-y. Chang, W. Liu, J. D. Baxter, S. K. Nordeen, Y. Wan, R. N. Day, and D. P. McDonnell
Temporally Distinct and Ligand-Specific Recruitment of Nuclear Receptor-Interacting Peptides and Cofactors to Subnuclear Domains Containing the Estrogen Receptor
Mol. Endocrinol., December 1, 2000; 14(12): 2024 - 2039.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
P. Bausero, M.-H. Ben-Mahdi, J.-P. Mazucatelli, C. Bloy, and M. Perrot-Applanat
Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia
Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2033 - H2042.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Tamir, M. Eizenberg, D. Somjen, N. Stern, R. Shelach, A. Kaye, and J. Vaya
Estrogenic and Antiproliferative Properties of Glabridin from Licorice in Human Breast Cancer Cells
Cancer Res., October 1, 2000; 60(20): 5704 - 5709.
[Abstract] [Full Text]

Home page
 NEJMHome page
R. T. Chlebowski
Reducing the Risk of Breast Cancer
N. Engl. J. Med., July 20, 2000; 343(3): 191 - 198.
[Full Text] [PDF]

Home page
 LupusHome page
S M Aronica, A Dozier, P Fanti, and M Nazareth
Altered bone marrow cell sensitivity in the lupus-prone NZB/W mouse: regulation of CFU-GM colony formation by estrogen, tamoxifen and thrombopoietin
Lupus, May 1, 2000; 9(4): 271 - 277.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
G. de Haan, S. Chusacultanachai, C. Mao, B. S. Katzenellenbogen, and D. J. Shapiro
Estrogen Receptor-KRAB Chimeras Are Potent Ligand-dependent Repressors of Estrogen-regulated Gene Expression
J. Biol. Chem., April 28, 2000; 275(18): 13493 - 13501.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. Morrow and S. J. Schnitt
Treatment Selection in Ductal Carcinoma In Situ
JAMA, January 26, 2000; 283(4): 453 - 455.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. M. Lippman and P. H. Brown
Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost
J Natl Cancer Inst, November 3, 1999; 91(21): 1809 - 1819.
[Full Text] [PDF]

Home page
 JCOHome page
V. C. Jordan
Tamoxifen: Too Much of a Good Thing?
J. Clin. Oncol., September 1, 1999; 17(9): 2629 - 2629.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Leygue, H. Dotzlaw, P. H. Watson, and L. C. Murphy
Expression of the Steroid Receptor RNA Activator in Human Breast Tumors
Cancer Res., September 1, 1999; 59(17): 4190 - 4193.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
V C. Jordan and M Morrow
Raloxifene as a multifunctional medicine?
BMJ, August 7, 1999; 319(7206): 331 - 332.
[Full Text]

Home page
 J. Biol. Chem.Home page
J. M. Hall, J. F. Couse, and K. S. Korach
The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling
J. Biol. Chem., September 28, 2001; 276(40): 36869 - 36872.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society